Patrick I. Borgen, MD, Discusses Upcoming Breast Cancer Conferences

Video

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Patrick I. Borgen, MD, chair of surgery and director of the Breast Cancer Program at Maimonides Medical Center, discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Transcription:

In December of this year, we will once again enjoy the San Antonio Breast Cancer Symposium. This is a very long running scientific meeting where a number of the seminal research discoveries over the years have been presented. And while we’re not supposed to really know what is coming out, I think that there are some very important clinical trials that are going to be unblinded and talked about. There are going to be some emerging agents that will play a bigger role. So, we are all very excited about San Antonio this year.

 

I will mention that while San Antonio shares where things are, it doesn’t really address how to apply them practically and I think that is where the Miami Breast Cancer Conference comes in to take the scientific knowledge from San Antonio and apply it practically. How do I take all of this information and apply it to the patient in front of me. And I think that is what Miami does.  

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content